scholarly journals Increment of serum C-peptide measured by glucagon test closely correlates with human relative beta-cell area

2015 ◽  
Vol 62 (4) ◽  
pp. 329-337 ◽  
Author(s):  
Yukari Fujita ◽  
Junji Kozawa ◽  
Hiromi Iwahashi ◽  
Syo Yoneda ◽  
Sae Uno ◽  
...  
Author(s):  
Takashi SAITO ◽  
Yasumasa UEHARA ◽  
Souichi SAEKI ◽  
Yukio TANIZAWA ◽  
Kohei UEDA

Diabetologia ◽  
2012 ◽  
Vol 55 (5) ◽  
pp. 1346-1354 ◽  
Author(s):  
J. J. Meier ◽  
T. G. K. Breuer ◽  
R. C. Bonadonna ◽  
A. Tannapfel ◽  
W. Uhl ◽  
...  

2010 ◽  
Vol 165 (2-3) ◽  
pp. 180-185 ◽  
Author(s):  
Chiara Montemurro ◽  
Christina U. Köhler ◽  
Waldemar Uhl ◽  
Andrea Tannapfel ◽  
Wolfgang E. Schmidt ◽  
...  
Keyword(s):  

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Anniek F. Lubberding ◽  
Jinyi Zhang ◽  
Morten Lundh ◽  
Thomas Svava Nielsen ◽  
Mathilde S. Søndergaard ◽  
...  

AbstractLoss-of-function (LoF) mutations in KCNQ1, encoding the voltage-gated K+ channel Kv7.1, lead to long QT syndrome 1 (LQT1). LQT1 patients also present with post-prandial hyperinsulinemia and hypoglycaemia. In contrast, KCNQ1 polymorphisms are associated with diabetes, and LQTS patients have a higher prevalence of diabetes. We developed a mouse model with a LoF Kcnq1 mutation using CRISPR-Cas9 and hypothesized that this mouse model would display QT prolongation, increased glucose-stimulated insulin secretion and allow for interrogation of Kv7.1 function in islets. Mice were characterized by electrocardiography and oral glucose tolerance tests. Ex vivo, islet glucose-induced insulin release was measured, and beta-cell area quantified by immunohistochemistry. Homozygous mice had QT prolongation. Ex vivo, glucose-stimulated insulin release was increased in islets from homozygous mice at 12–14 weeks, while beta-cell area was reduced. Non-fasting blood glucose levels were decreased at this age. In follow-up studies 8–10 weeks later, beta-cell area was similar in all groups, while glucose-stimulated insulin secretion was now reduced in islets from hetero- and homozygous mice. Non-fasting blood glucose levels had normalized. These data suggest that Kv7.1 dysfunction is involved in a transition from hyper- to hyposecretion of insulin, potentially explaining the association with both hypoglycemia and hyperglycemia in LQT1 patients.


Diabetologia ◽  
2021 ◽  
Author(s):  
Xuan Wang ◽  
Shady Younis ◽  
Jing Cen ◽  
Yun Wang ◽  
Camilla Krizhanovskii ◽  
...  

Abstract Aims/hypothesis ZBED6 (zinc finger, BED-type containing 6) is known to regulate muscle mass by suppression of Igf2 gene transcription. In insulin-producing cell lines, ZBED6 maintains proliferative capacity at the expense of differentiation and beta cell function. The aim was to study the impact of Zbed6 knockout on beta cell function and glucose tolerance in C57BL/6 mice. Methods Beta cell area and proliferation were determined in Zbed6 knockout mice using immunohistochemical analysis. Muscle and fat distribution were assessed using micro-computed tomography. Islet gene expression was assessed by RNA sequencing. Effects of a high-fat diet were analysed by glucose tolerance and insulin tolerance tests. ZBED6 was overexpressed in EndoC-βH1 cells and human islet cells using an adenoviral vector. Beta cell cell-cycle analysis, insulin release and mitochondrial function were studied in vitro using propidium iodide staining and flow cytometry, ELISA, the Seahorse technique, and the fluorescent probes JC-1 and MitoSox. Results Islets from Zbed6 knockout mice showed lowered expression of the cell cycle gene Pttg1, decreased beta cell proliferation and decreased beta cell area, which occurred independently from ZBED6 effects on Igf2 gene expression. Zbed6 knockout mice, but not wild-type mice, developed glucose intolerance when given a high-fat diet. The high-fat diet Zbed6 knockout islets displayed upregulated expression of oxidative phosphorylation genes and genes associated with beta cell differentiation. In vitro, ZBED6 overexpression resulted in increased EndoC-βH1 cell proliferation and a reduced glucose-stimulated insulin release in human islets. ZBED6 also reduced mitochondrial JC-1 J-aggregate formation, mitochondrial oxygen consumption rates (OCR) and mitochondrial reactive oxygen species (ROS) production, both at basal and palmitate + high glucose-stimulated conditions. ZBED6-induced inhibition of OCR was not rescued by IGF2 addition. ZBED6 reduced levels of the mitochondrial regulator PPAR-γ related coactivator 1 protein (PRC) and bound its promoter/enhancer region. Knockdown of PRC resulted in a lowered OCR. Conclusions/interpretation It is concluded that ZBED6 is required for normal beta cell replication and also limits excessive beta cell mitochondrial activation in response to an increased functional demand. ZBED6 may act, at least in part, by restricting PRC-mediated mitochondrial activation/ROS production, which may lead to protection against beta cell dysfunction and glucose intolerance in vivo. Graphical abstract


2011 ◽  
Vol 31 (4) ◽  
pp. 241-246 ◽  
Author(s):  
Olga Pivovarova ◽  
Eva Fisher ◽  
Katarzyna Dudziak ◽  
Iryna Ilkavets ◽  
Steven Dooley ◽  
...  

Chromosomal locus 6q23 is strongly linked to type 2 diabetes (T2DM) and related features including insulin secretion in various ethnic populations. Connective tissue growth factor (CTGF) gene is an interesting T2DM candidate gene in this chromosome region. CTGF is a key mediator of progressive pancreatic fibrosis up-regulated in type 2 diabetes. In contrast,CTGFinactivation in mice compromises islet cell proliferation during embryogenesis. The aim of our study was to investigate an impact ofCTGFgenetic variation on pancreatic beta-cell function and T2DM pathogenesis. We studied the effect of a commonCTGFpolymorphism rs9493150 on the risk of the T2DM development in three independent German cohorts. Specifically, the association betweenCTGFpolymorphism and non-invasive markers of beta-cell area derived from oral glucose tolerance test was studied in subjects without diabetes. Neither in the Metabolic Syndrome Berlin Potsdam (MESYBEPO) study (n= 1026) (OR = 0.637, CI (0.387–1.050);p= 0.077) nor in the European Prospective Investigation into Cancer and Nutrition-Potsdam (EPIC-Potsdam) (n= 3049) cohort (RR = 0.77 CI (0.49–1.20),p= 0.249 for the recessive homozygote in general model), a significant association with increased diabetes risk was observed. The risk allele of rs9493150 had also no effect on markers of beta-cell area in the combined analysis of the MESYBEPO and Tübingen Family Study (n= 1826). In conclusion, the polymorphism rs9493150 in the 5’-untranslated region of theCTGFgene has no association with T2DM risk and surrogate markers of beta-cell area.


2021 ◽  
Vol 35 (S1) ◽  
Author(s):  
Evann Fowler ◽  
Luis Mercado ◽  
Quiana Wilkerson‐Vidal ◽  
Madushika Wimalarathne ◽  
Sharifa Love‐Rutledge
Keyword(s):  

2016 ◽  
Vol 175 (5) ◽  
pp. 467-476
Author(s):  
Thomas G K Breuer ◽  
Laura Borker ◽  
Daniel R Quast ◽  
Andrea Tannapfel ◽  
Wolfgang E Schmidt ◽  
...  

Introduction Gastrin has been shown to promote beta-cell proliferation in rodents, but its effects in adult humans are largely unclear. Proton pump inhibitors (PPIs) lead to endogenous hypergastrinaemia, and improved glucose control during PPI therapy has been reported in patients with diabetes. Therefore, we addressed whether PPI treatment is associated with improved glucose homoeostasis, islet cell hyperplasia or increased new beta-cell formation in humans. Patients and methods Pancreatic tissue specimens from 60 patients with and 33 patients without previous PPI therapy were examined. The group was subdivided into patients without diabetes (n = 27), pre-diabetic patients (n = 31) and patients with diabetes (n = 35). Results Fasting glucose and HbA1c levels were not different between patients with and without PPI therapy (P = 0.34 and P = 0.30 respectively). Beta-cell area was higher in patients without diabetes than in patients with pre-diabetes or diabetes (1.33 ± 0.12%, 1.05 ± 0.09% and 0.66 ± 0.07% respectively; P < 0.0001). There was no difference in beta-cell area between patients with and without PPI treatment (1.05 ± 0.08% vs 0.87 ± 0.08%, respectively; P = 0.16). Beta-cell replication was rare and not different between patients with and without PPI therapy (P = 0.20). PPI treatment was not associated with increased duct-cell replication (P = 0.18), insulin expression in ducts (P = 0.28) or beta-cell size (P = 0.63). Conclusions These results suggest that in adult humans, chronic PPI treatment does not enhance beta-cell mass or beta-cell function to a relevant extent.


Sign in / Sign up

Export Citation Format

Share Document